Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing radiation treatment for prostate cancer

Urology

Volumn 62, Issue SUPPL. 1, 2003, Pages 36-45

  Pisansky, Thomas M ^a,b  

^a MAYO CLINIC   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; CYCLOPHOSPHAMIDE; CYPROTERONE; DIETHYLSTILBESTROL; ESTRAMUSTINE; FLUTAMIDE; GONADORELIN; GONADORELIN AGONIST; GOSERELIN; MEGESTROL; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; TUMOR PROTEIN;

ADJUVANT CHEMOTHERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER DIAGNOSIS; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; REVIEW; ADENOCARCINOMA; ADJUVANT THERAPY; CONTROLLED CLINICAL TRIAL; FORECASTING; LYMPH NODE METASTASIS; MALE; METASTASIS; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSPECTIVE STUDY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FORECASTING; GONADOTROPIN-RELEASING HORMONE; HUMANS; LYMPHATIC METASTASIS; MALE; MULTICENTER STUDIES; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 1842829895     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2003.08.004     Document Type: Article

References (40)

1. AJCC Cancer Staging Manual, 6th ed. New York: Springer-Verlag, 2002, pp. 309-313.
2. Pilepich MV, Krall JM, Sause WT, et al: Prognostic factors in carcinoma of the prostate: analysis of RTOG study 75-06. Int J Radiat Oncol Biol Phys 13: 339-349, 1987.
3. Zagars GK, Pollack A, and von Eschenbach AC: Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer 79: 1370-1380, 1997.
4. Roach M 3rd, Lu J, Pilepich MV, et al: Long-term survival after radiotherapy alone: Radiation Therapy Oncology Group prostate cancer trials. J Urol 161: 864-868, 1999.
5. Pisansky TM, Kahn MJ, Rasp GM, et al: A multiple prognostic index predictive of disease outcome following irradiation for clinically localized prostatic carcinoma. Cancer 79: 337-344, 1997.
6. Shipley WU, Thames HD, Sandler HM, et al: Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 281: 1598-1604, 1999.
7. Kattan MW, Zelefsky MJ, Kupelian PA, et al: Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 18: 3352-3359, 2000.
8. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37: 1035-1041, 1997.
9. Scherr D, Swindle PW, and Scardino PT: National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology 61: 14-24, 2003.
10. Green N, Bodner H, Broth E, et al: Improved control of bulky prostate carcinoma with sequential estrogen and radiation therapy. Int J Radiat Oncol Biol Phys 10: 971-976, 1984.
11. Spry NA, Meffan PM, Christie DRH, et al: Orchidectomy prior to definitive radiotherapy for localized prostatic cancer. Int J Radiat Oncol Biol Phys 34: 1045-1053, 1996.
12. Zagars GK, Pollack A, and von Eschenbach AC: Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation. Cancer 80: 764-775, 1997.
13. Zelefsky MJ, Lyass O, Fuks Z, et al: Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. J Clin Oncol 16: 3380-3385, 1998.
14. Zagars GK, Pollack A, and Smith LG: Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 44: 809-819, 1999.
15. D'Amico AV, Schultz D, Loffredo M, et al: Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA 284: 1280-1283, 2000.
16. Coughlin CT, Richmond RC, and Page RL: Platinum drug delivery and radiation for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 28: 1029-1038, 1994.
17. Khil MS, Kim JH, Bricker LJ, et al: Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiation therapy. Cancer J Sci Am 3: 289-296, 1997.
18. Pilepich MV, John MJ, Krall JM, et al: Phase II Radiation Therapy Oncology Group study of hormonal cytoreduction with flutamide and zoladex in locally advanced carcinoma of the prostate treated with definitive radiotherapy. Am J Clin Oncol 13: 461-464, 1990.
19. Pilepich MV, Buzydlowski JW, John MJ, et al: Phase II trial of hormonal cytoreduction with megestrol and diethyl-stilbestrol in conjunction with radiotherapy for carcinoma of the prostate: outcome results of RTOG 83-07. Int J Radiat Oncol Biol Phys 32: 175-180, 1995.
20. Zietman AL, Nakfoor BM, Prince EA, et al: The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: an in vitro and in vivo study. Cancer J Sci Am 3: 31-36, 1997.
21. Zietman AL, Prince EA, Nakfoor BM, et al: Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys 38: 1067-1070, 1997.
22. Gleave ME, Goldenberg SL, Chin JL, et al: Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 166: 500-506, 2001.
23. Pilepich MV, Winter K, John MJ, et al: Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50: 1243-1252, 2001.
24. Lawton CA, Winter K, Murray K, et al: Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49: 937-946, 2001.
25. Bolla M, Collette L, Blank L, et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360: 103-106, 2002.
26. Pilepich MV, Al-Sarraf M, Rotman M, et al: Adjuvant chemotherapy with adriamycin, cytoxan and cis-platinum in high-grade carcinoma of the prostate treated with definitive radiotherapy (RTOG pilot 81-12). Am J Clin Oncol 9: 135-138, 1986.
27. Schmidt JD, Gibbons RP, Murphy GP, et al: Evaluation of adjuvant estramustine phosphate, cyclophosphamide, and observation only for node-positive patients following radical prostatectomy and definitive irradiation. Prostate 28: 51-57, 1996.
28. Green N, Bodner H, Broth E, et al: Response of lymph node metastasis to sequential estrogen and radiation therapy in prostate carcinoma. Urology 18: 137-142, 1981.
29. Pilepich MV, Krall JM, John MJ, et al: Hormonal cytoreduction in locally advanced carcinoma of the prostate treated with definitive radiotherapy: preliminary results of RTOG 83-07. Int J Radiat Oncol Biol Phys 16: 813-817, 1989.
30. Leverdière J, Gomez JL, Cusan L, et al: Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 37: 247-252, 1997.
31. Roach M III, DeSilvio M, Lawton C, et al: Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21: 1904-1911, 2003.
32. Garnick MB, Fair WR, Bostwick D, et al: Overview consensus statement: Fifth International Conference on Neoadjuvant Hormonal Therapy for Prostate Cancer. Mol Urol 4: 89-92, 2000.
33. Byar DP, and Corle DK: VACURG randomized trial of radical prostatectomy for stages I and II prostate cancer. Urology 27(suppl): 7-11, 1991.
34. Zagars GK, Johnson DE, von Eschenbach AC, et al: Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized trial. Int J Radiat Oncol Biol Phys 14: 1085-1091, 1988.
35. Schmidt JD, Gibbons RP, Murphy GP, et al: Adjuvant therapy for localized prostate cancer. Cancer 71: 1005-1013, 1993.
36. Granfors T, Modig H, Damber JE, et al: Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol 159: 2030-2034, 1998.
37. Iversen P, Tyrrell CJ, Kaisary AV, et al: Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 51: 389-396, 1998.
38. Wirth M, Tyrrell C, Wallace M, et al: Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology 58: 146-151, 2001.
39. See WA, Wirth MP, McLeod DG, et al: Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer Program. J Urol 168: 429-435, 2002.
40. Lawton CA, Winter K, Byhardt R, et al: Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Int J Radiat Oncol Biol Phys 38: 931-939, 1997.